Skip to main content
. Author manuscript; available in PMC: 2020 May 2.
Published in final edited form as: Pancreatology. 2019 Nov 21;20(1):101–109. doi: 10.1016/j.pan.2019.11.011

Figure 2. Expression of HH pathway components in paired patient biopsy samples.

Figure 2.

A. The table represents expression patterns of P-GLI1-S84 in pre- and post-treatment paired tumor biopsy samples. The level of P-GLI1-S84 expression was significantly decreased following combined Vismodegib and Erlotinib treatment in the majority of paired patient samples. B. A representative IHC image of change in P-GLI1-S84 expression from pre- to post-treatment. P-GLI1-S84 is mainly seen in the stroma. C. Expression levels of various HH pathway components measured by qRT-PCR before (gray bars) and after (black bars) treatment. Expression is normalized to the 18S housekeeping gene. RNA expression levels of GLI1 in all paired patient biopsies evaluated were decreased following treatment when compared to baseline. Most samples showed no change in levels from baseline for PTCH1 or SHH. BCL2, a downstream target of GLI1, was decreased in four of the seven paired samples.